Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | CRHBP | P24387 | 1/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | JUN | P05412 | 1/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6377755 | 0.86 | CYP2A6 (0.61) | CYP2A6SMN1; SMN2CA1CA2ALDH1A1 | |
| SCHEMBL73676 | 0.84 | CYP2A6 (0.60) | CYP2A6SMN1; SMN2CA1CA2ALDH1A1 | |
| SCHEMBL2534944 | 0.81 | CYP2A6 (0.53) | CYP2A6SMN1; SMN2CA1CA2ALDH1A1 | |
| SCHEMBL10950583 | 0.79 | CYP2A6 (0.54) | CYP2A6SMN1; SMN2CA1CA2ALDH1A1 | |
| SCHEMBL9400071 | 0.77 | CYP2A6 (0.49) | CYP2A6SMN1; SMN2CA1CA2MAPT | |
| SCHEMBL31495877 | 0.77 | CYP2A6 (0.60) | CYP2A6SMN1; SMN2CA1CA2ALDH1A1 | |
| SCHEMBL8486768 | 0.76 | CYP2A6 (0.59) | CYP2A6SMN1; SMN2CA1CA2MAPT | |
| SCHEMBL2248829 | 0.75 | CYP2A6 (1.00) | CYP2A6SMN1; SMN2CA1CA2ALDH1A1 | |
| SCHEMBL91157 | 0.74 | CYP2A6 (0.67) | CYP2A6SMN1; SMN2CA1CA2ALDH1A1 | |
| SCHEMBL655428 | 0.74 | CYP2A6 (1.00) | CYP2A6SMN1; SMN2CA1CA2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082372-A1 | Arylmethylene Substituted N-Acyl-Beta-Amino Alcohols | BAYER SCHERING PHARMA AG (DE) | 2009-03-26 | — | — | US | claimed |
| WO-2009013354-A1 | ARYLMETHYLENE SUBSTITUTED N-ACYL-β-AMINO ALCOHOLS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-29 | — | — | WO | claimed |
| EP-2018859-A1 | Arylmethylene substituted N-acyl-beta-amino alcohols | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-01-28 | — | — | EP | claimed |
| US-20090082372-A1 | Arylmethylene Substituted N-Acyl-Beta-Amino Alcohols | BAYER SCHERING PHARMA AG (DE) | 2009-03-26 | — | — | US | disclosed |
| WO-2009013354-A1 | ARYLMETHYLENE SUBSTITUTED N-ACYL-β-AMINO ALCOHOLS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-29 | — | — | WO | disclosed |
| EP-2018859-A1 | Arylmethylene substituted N-acyl-beta-amino alcohols | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-01-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082372-A1 | Arylmethylene Substituted N-Acyl-Beta-Amino Alcohols | FSHR, SHBG, NAT1 | CYP2A6 477/4885SMN1; SMN2 2238/4885CA1 4211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.